What Changed
- New SEC filings posted: Kalaris Therapeutics 10-K [1] and AN2 Therapeutics 8-K/10-K [2][3].
- As indexed, none indicate new cyber incidents or material operational impacts.
Cross-Source Inference
Observed facts:
- SEC index entries for Kalaris 10-K and AN2 8-K/10-K were posted today [1][2][3].
- No incident-bearing headlines or Item 1.05/8.01 flags are visible at index level.
Assessments:
- The absence of incident-specific cues in both issuers’ filings suggests no new, material cybersecurity disclosures today (medium confidence), contingent on full-text review as exhibits become available [1][2][3].
- Systemic risk posture remains unchanged given both are life sciences issuers with limited direct critical-infrastructure footprint (medium confidence), though sectoral supply-chain IT vendors could still pose indirect exposure.
Implications and What to Watch
- Actions now:
- Pull and scan full-text 10-K/8-K sections on Risk Factors, Legal Proceedings, and any Item 1.05 Cybersecurity Incidents once available.
- Check Kalaris and AN2 investor relations/press pages for any parallel notices.
- Triggers to monitor (next 72 hours):
- Any amended 8-Ks (especially Item 1.05) or subsequent 8-Ks referencing cybersecurity.
- Unusual outage reports from CROs/CMOs or shared SaaS vendors servicing multiple biotech issuers.
- If no amendments surface, downgrade active monitoring for these issuers to routine cadence.